Miracell Develops Stem Cell Therapy Targeting Colon Cancer
[Kookmin Ilbo] February 6, 2018 High value-added new technologies are expected to receive attention during industrialization. Stem cell specialist Miracell Co., Ltd. (CEO Shin Hyun-soon, pictured) announced on the 5th that it has successfully developed a blood-derived immune cell and stem cell treatment targeting colon cancer.This treatment is made primarily from blood-derived immune cells and stem cells isolated and extracted using Miracell’s proprietary cell separation and concentration technology.In vitro cell experiments verifying safety and efficacy demonstrated outstanding anticancer effects.Shin Hyun-soon, CEO of Miracell, stated, “Because the treatment preparation period is very short, we expect this technology to gain recognition as a high-value-added new technology if commercialized.” Miracell is also developing minimally invasive stem cell treatment separation and extraction technologies useful for treating cartilage regeneration, lower extremity ischemia, and myocardial infarction, and is currently pursuing marketing approval. Medical Reporter Lee Ki-soo
Cell banking company Miracell differentiates itself with superior cell recovery rates.
[Medical News] March 21, 2018 Requests for partnerships from Thailand, China, Hong Kong, and other countries Stem cell specialist Miracell announced on the 21st that it has expanded its stem cell storage business by partnering with Smart Stem Cell Co., Ltd., following its recent partnership with the International Mira Stem Cell Bank.Leveraging Miracell’s cell storage technology, Smart Stem Cell Banking is a total premium cell banking solution that includes stem cells, immune cells, and the growth factors they secrete, isolated from blood, bone marrow, and adipose tissue.Miracell stated, “Unlike existing cell banks, Smart Stem Cell Banking offers superior cell recovery rates and a concentrated concentration of beneficial growth factors.Furthermore, a premium health check package is available.”Miracell has developed a program that predicts and manages disease or aging through DNA analysis, cell health testing, biological age testing, and telomere testing.By simultaneously storing both stem cells and immune cells, Smart Stem Cell Banking promises greater efficacy as a personalized autologous cell therapy.The diverse growth factors contained within this solution enable faster and more effective results. Cell banking is expected to serve as a sustainable stepping stone to ensuring a healthy future for humanity.Miracell stated, “We have established a system that allows for immediate use after banking in collaboration with hospitals across our nationwide network.We are lowering various barriers to entry to make stem cell therapy more accessible to the general public.” Recently, Miracell has been receiving significant interest in Miracell’s cell storage business from countries such as Thailand, Vietnam, Hong Kong, Indonesia, and China. Miracell is currently pursuing the establishment of institutions in partnership with several Southeast Asian countries through this system.
Cell banking company Miracell on the rise
[Health Focus] March 21, 2018 Distinctive cell recovery rates… Partnership requests from Thailand, China, Hong Kong, and other countries. From birth to death, every human being must experience aging and disease at least once. Is aging inevitable? Can stem cell banking help us prepare for aging? Miracell Co., Ltd., a stem cell specialist, recently expanded its stem cell storage business by partnering with Smart Stem Cell Co., Ltd., following its partnership with the International Mira Stem Cell Bank. According to Maracell, Smart Stem Cell Banking is a total premium cell banking solution that includes stem cells, immune cells, and the growth factors they secrete, isolated from blood, bone marrow, and adipose tissue. Unlike conventional cell banks, Smart Stem Cell Banking offers superior cell recovery rates and a concentrated concentration of beneficial growth factors. Furthermore, the company has developed a program that can predict and manage disease or aging through a premium health check package that includes DNA analysis, cell health tests, biological age tests, and telomere tests. Simultaneous storage of both stem cells and immune cells can be expected to yield even greater results as a personalized autologous cell therapy. Furthermore, the various growth factors contained in this composition can lead to faster and more enhanced results. Cell banking is expected to serve as a sustainable stepping stone to ensuring a healthy future for humanity. Miracell has established a system in collaboration with hospitals across its nationwide network to enable immediate use of stem cell banking. To popularize stem cell therapy, it is lowering various barriers to entry to facilitate accessibility. Recently, Miracell has shown significant interest in its cell banking business, attracting visits from countries such as Thailand, Vietnam, Hong Kong, Indonesia, and China. Miracell is also pursuing the establishment of institutions in several Southeast Asian countries through partnerships with this system. Reporter Jang Young-sik sasilbodo@daum.net
Miracell Expands Stem Cell Storage Business Through Partnership with Smart Stem Cell
[Kyunghyang Shinmun] March 21, 2018 Miracell, a stem cell company, announced on the 21st that it has expanded its stem cell storage business by partnering with Smart Stem Cell, Inc., following its partnership with the International Mira Stem Cell Bank. This cell banking business encompasses stem cells, immune cells, and the growth factors they secrete, isolated from blood, bone marrow, and adipose tissue. A company representative stated, “Its unique characteristics include its superior cell recovery rate and the concentration of beneficial growth factors.” “We have developed a program that can predict and manage disease and aging through DNA analysis, cell health testing, biological age testing, and telomere (the end of chromosomes) testing.” Cell banking refers to storing healthy cells, similar to depositing them in a bank. If a patient develops cancer, their own cells can be used for treatment. This is one of the ethically sound regenerative treatments. The cell banking storage period is approximately 30 to 40 years. Miracell has established a system in collaboration with hospitals nationwide to ensure that cells can be used at any time after banking. A company representative said, “Recently, Miracell has been receiving visits from countries such as Thailand, Vietnam, Hong Kong, Indonesia, and China, expressing great interest in Miracell’s cell storage business.” Reporter Park Hyo-sun anytoc@kyunghyang.com
Stem cell therapy for cartilage defects…Recognized as a limited medical technology.
[Edaily] June 11, 2018 Stem cell therapy for cartilage defects has been recognized as a limited new medical technology, making selective treatment possible. According to Miracell Co., Ltd. (CEO Shin Hyun-soon) on the 11th, autologous stem cell therapy for knee cartilage defects was previously only available to patients aged 15 to 50. However, with this new recognition as a limited new medical technology, stem cell treatment can now be performed at medical institutions that have applied for the treatment. Miracell is a stem cell company that has received approval and certification for its stem cell isolation and treatment technologies from the Korea Food and Drug Administration (KFDA), the Ministry of Health and Welfare, and the New Medical Technology Assessment Division since 2009. The company possesses proprietary stem cell technology and holds 11 patents, one PCT application, 15 trademarks and service marks, and 10 designs as related intellectual property rights. CEO Shin Hyun-soon stated, “Previously, the age limit was 15 to 50, but with this approval, medical institutions that apply for treatment can now apply for arthritis treatment without any age restrictions.” In the past, cartilage loss and degenerative arthritis were considered incurable due to the inherent difficulty of cartilage repair once damaged. This meant pain relief was endured with anti-inflammatory medications, and when the pain worsened, joint replacement surgery was performed. However, autologous stem cell therapy has recently made it possible to regenerate cartilage in early and mid-stage arthritis, restoring the knee to its former health. CEO Shin emphasized, “Autologous stem cell therapy is a simpler treatment method compared to osteoarthritis surgery, yet it offers promising results.”
International St. Mary’s selected for national research and development of stem cell therapy
[Medical Times] June 22, 2018 Stem cell therapy selected as a research project generating results among 44 projects in 12 fields. Catholic Kwandong University International St. Mary’s Hospital (Director Kim Young-in) announced on the 21st that stem cell-based regenerative therapy has been selected as a nationally recognized health and medical technology research and development project.In December of last year, the Ministry of Health and Welfare and the Korea Health Industry Development Institute selected stem cell therapy as a high-yield research project among 44 projects in 12 fields. Chae Dong-sik, Director of the International St. Mary’s Hospital Cell Therapy Center, where this research will be conducted, stated, “The selection of this research project was due to the fact that International St. Mary’s Hospital has established and operates a bio-convergence research center and a cell therapy center.” Professor Chae Dong-sik (Orthopedic Surgery) has been conducting clinical trials on the treatment of degenerative knee arthritis using autologous bone marrow and adipose-derived stem cells since 2015, targeting patients aged 50 and older.Professor Chae’s clinical trial, now in its fourth year, focuses on regenerating lost knee cartilage using autologous stem cells, which do not require separate culture. Professor Chae stated, “Using Miracell’s Smart Prep 2 BMAC system, a new medical technology, autologous bone marrow stem cell transplantation has resulted in cartilage regeneration of over 70%, with no adverse effects to date.” The research team at International St. Mary’s Hospital plans to develop a complex, enhanced stem cell treatment using a new tissue regeneration technology and apply it to an animal model.The goal of this research project is to apply animal models to stem cell therapy clinical studies, progressing to Phase 1 clinical trials, and evaluate their efficacy and safety.The research team will optimize technologies to eliminate incomplete regeneration and develop a complex, enhanced stem cell treatment (at the International St. Mary’s Hospital Bio-Convergence Research Center). They will also develop evaluation techniques for incomplete regeneration that occurs with existing stem cell treatments and apply them to Phase 1 clinical trials (at the International St. Mary’s Hospital Cell Therapy Center).Furthermore, the team plans to develop animal models and establish standards for verifying efficacy and safety (at the Chonbuk National University College of Veterinary Medicine). Professor Chae Dong-sik said, “If this research is successful, it will contribute to improving national health by developing a treatment for degenerative knee arthritis with improved side effects. Furthermore, it is expected to elevate the national status in the field of stem cell and tissue regeneration by securing complete technology.” Reporter Lee Ji-hyun news@medicaltimes.com
Stem Cell Treatment of Diabetic Critical Limb Ischemia Opens the Way
[Financial News] June 23, 2018 Soonchunhyang University Bucheon Hospital begins full-scale patient recruitment. A path has been opened to treat diabetic severe limb ischemia using autologous bone marrow stem cells.Miracell, a stem cell company, announced on the 23rd that its BMAC (Bio-Mechanical Axon Modulator) is effective in treating patients with diabetic severe limb ischemia. Autologous bone marrow stem cell therapy has been selected as a limited medical technology for the treatment of diabetic severe limb ischemia, a devastating condition that sometimes requires limb amputation. A support program has begun in earnest to establish clinical evidence for promising medical technologies in the research phase, where safety has been confirmed but clinical efficacy has been challenging to demonstrate. The limited medical technology assessment system allows patients with technologies that are not currently being introduced to Korean hospitals due to insufficient research on their therapeutic efficacy to receive treatment at hospitals and physicians designated by the Minister of Health and Welfare, provided that such technologies are available only when there are no other treatments available or when rapid adoption is required for patients with rare diseases. We heard about the treatment outlook from Dr. Eun-soo Park, head of the department at Soonchunhyang University Bucheon Hospital, who is in charge of ‘Autologous bone marrow stem cell therapy for diabetic severe lower extremity ischemia’ and is currently recruiting patients. ―What is autologous bone marrow stem cell therapy for diabetic critical limb ischemia?▲The number of patients with diabetes is rapidly increasing, currently reaching approximately 10% of the general population. Of these, 10-20% develop foot ulcers. These foot ulcers account for approximately 25% of all diabetes-related hospitalizations, and a significant number of these patients require limb amputation. Peripheral vascular disease is the most important factor in the development of diabetic foot ulcers, and the average treatment period for diabetic critical limb ischemia is over six months. Conventional treatments, such as transplantation or intervention, are significantly limited. Therefore, given the positive clinical trial reports on novel stem cell-based treatments, this clinical study aims to demonstrate the efficacy of autologous stem cell therapy for diabetic critical limb ischemia and establish a treatment method. What is the purpose of autologous bone marrow stem cell therapy for diabetic critical limb ischemia?▲This study investigated the clinical efficacy of autologous stem cells in improving diabetic critical limb ischemia. The aim was to apply autologous bone marrow-derived cells to patients with diabetic critical limb ischemia to induce angiogenesis, delay foot amputation, heal skin ulcers, and improve functional outcomes. The purpose of this study was to evaluate the efficacy of autologous bone marrow stem cells in improving critical limb ischemia and to determine the potential complications or side effects. What is “autologous bone marrow stem cell therapy for diabetic critical limb ischemia”?▲This limited medical technology involves harvesting bone marrow, concentrating it, and then injecting it intramuscularly into the targeted area for patients with diabetic critical limb ischemia who are refractory to or unresponsive to conventional treatments. By promoting angiogenesis and healing skin ulcers, the goal is to ultimately prevent foot amputations in patients suffering from diabetic critical limb ischemia. ―Eligibility for study participation:① Age (male or female, 19 to 80 years of age).② Patients diagnosed with diabetes and receiving oral medication or insulin therapy, or newly diagnosed with diabetes.③ Patients who are unable or have failed bypass surgery.④ Patients diagnosed with severe lower extremity ischemia (Rutherford classification 4-5) and experiencing symptoms despite conservative treatment. Symptoms include resting pain, non-healing wounds or gangrene of the belos metatarsals, an ankle-brachial index (ABI) < 0.7, or an ABI ≥ 0.7, but with toes that do not have a toe-brachial index (TBI) or arterial waveforms measured on plethysmography.⑤ Participants must be willing and able to consent to the study, sign the consent form, and comply with the study requirements. pompom@fnnews.com Jeong Myeong-jin, Medical Reporter
Miracell Introduces New CI
[Health News] July 5, 2018 Developing into a future-oriented and global company Miracell (CEO Shin Hyun-soon), a stem cell specialist company, recently revamped its corporate identity (CI). The new CI embodies the company’s aspirations for growth as a future-oriented, global company. The small circle symbolizes stem cells, signifying the convergence of technology and the miracles achieved by cells. Miracell specializes in the wholesale of medical and scientific devices, including stem cell medical devices, cosmetics, trade, and e-commerce. The company’s name, Miracell, is a portmanteau of “Miracel” and “Cell,” which means “miracle” in Latin. As a stem cell specialist company that respects life and pursues a healthy lifestyle, Miracell embodies the company’s vision of creating miracles of healing, as embodied by the name “Mira.” Miracell collaborates with domestic and international medical institutions to specialize in safe stem cell therapy, conducting research and development.As a leading company in advanced medical technology that prioritizes not only disease treatment but also ethics and morality, Miracell aims to contribute to the development of hospitals and the improvement of public health. Currently, Miracell’s stem cell treatment for diabetic lower extremity ischemia and knee osteoarthritis have been designated as limited new medical technologies and are eligible for new support from the Health and Medical Technology Research and Development Project. Professor Chae Dong-sik (Orthopedic Surgery) at Catholic Kwandong University International St. Mary’s Hospital has demonstrated cartilage regeneration rates of over 70% using autologous bone marrow stem cell transplantation using Miracell’s SmartPRep2 BMAC system, a new medical technology. Professor Eun-soo Park (Plastic Surgery) of Soonchunhyang University Bucheon Hospital is using Miracell’s SmartPrap 2 Bi-MAC system to provide autologous bone marrow stem cell therapy for diabetic lower extremity ischemia, giving hope to patients who previously had to undergo limb amputation. CEO Hyun-soon Shin stated, “With this CI change, we will dedicate company-wide efforts to further advancing as a future-oriented, global company.” By Joong-sun Lim jslim1971@bokuennews.com